Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Acquires $117,500.00 in Stock

Posted by on Jul 4th, 2026

Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson bought 5,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were acquired at an average price of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the transaction, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. This trade represents a 11.99% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ FTH opened at $22.92 on Friday. Sensei Biotherapeutics, Inc. has a 1 year low of $6.32 and a 1 year high of $36.76.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. As a group, equities research analysts anticipate that Sensei Biotherapeutics, Inc. will post -16.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

FTH has been the topic of a number of analyst reports. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price on the stock. HC Wainwright started coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $60.00 target price on the stock. Finally, Weiss Ratings started coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $58.50.

Check Out Our Latest Research Report on FTH

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.

Featured Stories

Insider Buying and Selling by Quarter for Sensei Biotherapeutics (NASDAQ:FTH)

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.